New Market Report Now Available: United States Pharmaceuticals & Healthcare Report Q4 2013
Multinational drugmakers with higher exposure to the US pharmaceutical market will outperform rivals with established presences in Western Europe and emerging markets. The former region is under pressure from austerity-induced medicine price cuts, and many markets will experience significant contractions in 2013. Meanwhile, the latter is seeing currency weakness and deepening industry-specific challenges, such as the bribery/corruption scandal in China. The US remains highly attractive due to the willingness of payers to reimburse patients for high-value patented pharmaceuticals.
View full press release